Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Inclusion Criteria:

1. Written informed consent/assent, according to local guidelines, signed by the adultpatients. In the population under 18 years, it will be signed by the patient and/orby the parents or legal guardian prior to enrolling in the rollover study andreceiving study medication

2. SCD patient currently enrolled in a Novartis-sponsored study receiving crizanlizumaband has fulfilled all the requirements in the parent study. Patient is currentlybenefiting from the treatment with crizanlizumab as determined by the investigatorand has completed the treatment schedule as planned in the parent study

3. Patient has demonstrated compliance to the planned visit schedule in the parentstudy, and in the opinion of the investigator has shown willingness and ability tocomply with future visit schedules

Exclusion Criteria:

1. Patient had permanently discontinued from crizanlizumab study treatment in theparent study before the parent study completion

2. Ongoing/unresolved treatment-related Grade 3 or higher AEs, and/or any ongoing AErequiring dose interruption. Patients meeting all other eligibility criteria may beenrolled once toxicities have resolved unless those toxicities were grade 4

3. Concurrent participation in any other investigational clinical trial other than theparent study or plan to participate in any other investigational clinical trial

4. Pregnant or nursing women

5. Women of childbearing potential who are unwilling to be on highly effectivecontraceptives during dosing and until 15 weeks after stopping treatment withcrizanlizumab

6. SCD patients who do not meet parent study protocol criteria to continue withcrizanlizumab